Outcomes for BioCartilage® Extracellular Matrix Versus Microfracture for Talar Osteochondral Lesions

Mark C. Drakos, MD (New York, NY), presents clinical findings on the treatment of talar osteochondral lesions with BioCartilage® extracellular matrix and bone marrow aspirate (BMA) versus microfracture. Dr. Drakos reports a 2-year postoperative reoperation rate of nearly 28% when using microfracture alone, compared to a reoperation rate of less than 5% when BioCartilage matrix and BMA were incorporated.